文献速递淋巴瘤造血干细胞移植与细胞治疗

日本全国登记分析:大B细胞淋巴瘤CAR-T疗效随时间改善的驱动因素

Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.
PubMed 文献 · Blood Adv · 2026-01-01

该研究分析日本登记数据库中913例复发/难治性大B细胞淋巴瘤患者,比较2019-2021与2022-2024两个日历期的结局。

要点

  • 二线治疗、输注前疾病控制改善及产品选择变化是疗效改善的主要驱动因素。

核心结论

  • 真实世界CD19 CAR-T治疗复发/难治性LBCL的结局已改善,主要由二线治疗、输注前疾病控制改善及更多使用强效CAR-T产品驱动。

研究设计与样本

  • 基于日本全国登记数据库分析913例复发/难治性大B细胞淋巴瘤患者,比较2019-2021与2022-2024两个日历期的结局。

主要发现

  • 6个月非复发死亡率保持低位(2.1% vs 1.5%)。

关键数值与推荐

  • 多因素分析确定二线治疗、输注前疾病控制改善及产品选择从tisagenlecleucel转向axi-cel或liso-cel为改善的主要驱动因素。

临床怎么用

  • 在真实世界临床中,优化CAR-T治疗时机(如二线使用)、加强输注前疾病控制及合理选择CAR-T产品可能改善复发/难治性LBCL患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of outcomes remain unclear. This study analyzed 913 patients with relapsed/refractory (R/R) LBCL from a Japanese registry and compared the outcomes between 2 calendar periods (2019-2021 vs 2022-2024). The 2022-2024 cohort was older, had more adverse baseline features, and was less pretreated. Treatment patterns have shifted toward higher utilization of second-line therapy, a growing preference for axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and improved disease control before infusion. Accordingly, the 2022-2024 cohort achieved a longer progression-free survival (PFS; 6-month PFS, 63.2% vs 55.2%; P = .005), which persisted after adjusting for baseline characteristics using propensity score matching. Multivariable analysis identified second-line therapy, improved preinfusion disease control, and a shift in product selection from tisagenlecleucel to axi-cel or liso-cel as the primary drivers of this improvement. This benefit was pronounced in high-risk populations, including patients with stable or progressive disease at infusion (6-month PFS, 54.6% vs 43.8%; P = .012) and those who were refractory to first-line therapy (6-month PFS, 51.7% vs 40.3%; P = .013). Despite broader use in higher-risk populations and greater axi-cel exposure, 6-month nonrelapse mortality remained low (2.1% vs 1.5%). Real-world outcomes of CD19 CAR T-cell therapy for R/R LBCL have improved, predominantly driven by second-line therapy, enhanced preinfusion disease control, and increased use of more potent CAR T products.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Yagi Y, Kanemasa Y, Terao T, et al. Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis. Blood Adv. 2026. PMID: 42018609. doi:10.1182/bloodadvances.2025019510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。